Companies
- Companies
- Company details
Adherex Technologies Incorporated
Out-licensing
Clinical Development of Eniluracil for the Treatment of Hepatocellular Cancer and Taxane- and Anthracycline-resistant Breast Cancer More
Development of Novel Anticancer Therapeutics: OB-Cadherin Antagonists with Anti-Metastatic Activity More
Development of Small Molecule N-Cadherin Antagonists: Attacking the Progression of Cancer More
Phase II Clinical Development of ADH-1: Targeting N-cadherin in the Treatment of Cancer More
Prevention of Platinum-Based Cancer Chemotherapy Hearing Loss: Phase III Clinical Development of Sodium Thiosulphate More
Towards the Development of Novel Angiolytics for Cancer Therapy: Application of VE-Cadherin Antagonists More
Related Reports
Market Research Reports provided by reports.iptechex.com
May 2011 - 64 pages - $500
Nov 2010 - 69 pages - $500
Feb 2011 - 27 pages - $125
May 2011 - 34 pages - $125
Sep 2011 - 78 pages - $500
Nov 2010 - 92 pages - $600
Nov 2010 - 55 pages - $750
Mar 2011 - 89 pages - $250
Nov 2010 - 32 pages - $600
Feb 2010 - 24 pages - $99
Contact details
Robin Norris
Head office
Adherex Technologies Incorporated
4620 Creekstone Drive, Suite 200
Durham
27703
North Carolina (USA)
4620 Creekstone Drive, Suite 200
Durham
27703
North Carolina (USA)
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us